Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers
Authors:
- Inci AlacaciogluIAInci Alacacioglu
- Serife S. MedeniSMSerife S. Medeni
- Guner H. OzsanGOGuner H. Ozsan
- Bahriye PayzinBPBahriye Payzin
- O. Gokmen SevindikOSO. Gokmen Sevindik
- Celal AcarCACelal Acar
- Abdullah KatgiAKAbdullah Katgi
- Fusun OzdemirkanFOFusun Ozdemirkan
- Ozden PiskinOPOzden Piskin
- Mehmet A. OzcanMOMehmet A. Ozcan
- Bulent UndarBUBulent Undar
- Fatih DemirkanFDFatih Demirkan
- 1 January 2014
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 60 (4) , 219-223
Abstract
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens. In this study, we wanted to evaluate the outcome of 50 adult ALL patients treated with BFM (i.e. Berlin-Frankfurt-Munster, n = 20) and hyper-CVAD (n = 30) protocols between March 2006 and October 2012. The median age was 25 years in the BFM group and 30.5 years in the hyper-CVAD group with a male/female ratio of 15:5 and 17:13, respectively. Forty-five percent of the patients in the BFM group and 30.3% in the hyper-CVAD group were <25 years old. The majority of cases were B cell in origin (80% in the BFM group and 70% in the hyper-CVAD group). Complete remission after induction therapy was achieved in 95 and 96% of the patients, respectively. The median follow-up time was 37 months. The 5-year survival rate was higher in the BFM group than in the hyper-CVAD group (59 vs. 34%). There were also no complications which could cause a delay during the hyper-CVAD regimen. Both chemotherapies were well tolerated. None of the patients died from drug-related toxicity. Only mild liver enzyme elevations were seen as toxicity in the BFM group; these did not cause any delay in therapy. The BFM regimen seems to be feasible for adult patients with ALL in terms of tolerability and efficacy, especially in young adults.Keywords
This publication has 11 references indexed in Scilit:
- L-Carnitine Ameliorates L-Asparaginase-Induced Acute Liver Toxicity in Steatotic Rat LiversChemotherapy, 2013
- Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 StudyJournal of Clinical Oncology, 2009
- Treatment of Adult Acute Lymphoblastic LeukemiaSeminars in Hematology, 2009
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemiaLeukemia & Lymphoma, 2008
- Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained settingLeukemia & Lymphoma, 2007
- Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemiaCancer, 2006
- Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocolsPediatric Blood & Cancer, 2006
- INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURESThe Lancet, 1988
- Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen*Klinische Padiatrie, 1981